Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interim Marketing Of New Conditions Prohibited Under Proposed Rule

This article was originally published in The Tan Sheet

Executive Summary

Final monograph status would be required before a new OTC condition could be sold in the U.S. under FDA's proposed rule on "material time, material extent" published in the Federal Register Dec. 20. Interim marketing of conditions deemed eligible for monograph consideration would not be allowed.
Advertisement

Related Content

FDA “Material Time, Material Extent” Rule May Be Cloudy For Sunscreens
FDA “Material Time, Material Extent” Rule May Be Cloudy For Sunscreens
FDA “Material Time, Material Extent” Rule May Be Cloudy For Sunscreens

Topics

Advertisement
UsernamePublicRestriction

Register

PS090723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel